ARDS - アリディス・ファ―マシュ―ティカルズ (Aridis Pharmaceuticals Inc.) アリディス・ファ―マシュ―ティカルズ

 ARDSのチャート


 ARDSの企業情報

symbol ARDS
会社名 Aridis Pharmaceuticals Inc (アリディス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aridis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies such as rise in drug resistance short duration of response negative impact on the human microbiome and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections primarily hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its lead product candidate AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M mAb targeting P. aeruginosa serotype O11.   アリディス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、感染症に対する免疫療法の開発・商業化に従事する。完全ヒトモノクロナ―ル抗体を用いて、薬物耐性や短い薬効時間、ヒトのミクロバイオ―ムへの悪影響などの治療の欠点を克服するように設計され、同社の差別化抗体発見プラットフォ―ムを使用する。本社所在地はカリフォルニア州サンノゼ。   Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.
本社所在地 5941 Optical Ct. San Jose CA 95138 USA
代表者氏名
代表者役職名
電話番号 +1 408-385-1742
設立年月日 2003年
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数 30人
url www.aridispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ards
adr_tso
EBITDA EBITDA(百万ドル) -21.68200
終値(lastsale) 12.8254
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 100.48690
売上高 売上高(百万ドル) 1.16000
企業価値(EV) 企業価値(EV)(百万ドル) 161.21890
当期純利益 当期純利益(百万ドル) -22.02800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aridis Pharmaceuticals Inc revenues increased from $44K to $344K. Net loss applicable to common stockholders decreased 35% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $4.6M (expense) to $3M (income).

 ARDSのテクニカル分析


 ARDSのニュース

   Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020  2020/11/24 10:30:00 PR Newswire
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat…
   Aridis Pharmaceuticals Announces Third Quarter 2020 Results  2020/11/20 21:05:00 PR Newswire
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the…
   Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel  2020/10/27 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH…
   Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Lowered by Zacks Investment Research  2020/10/21 17:08:41 The Olympia Report
Aridis Pharmaceuticals (NASDAQ:ARDS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to […]
   Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering  2020/10/14 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered…
   Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020  2020/11/24 10:30:00 PR Newswire
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat…
   Aridis Pharmaceuticals Announces Third Quarter 2020 Results  2020/11/20 21:05:00 PR Newswire
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the…
   Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel  2020/10/27 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH…
   Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Lowered by Zacks Investment Research  2020/10/21 17:08:41 The Olympia Report
Aridis Pharmaceuticals (NASDAQ:ARDS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to […]
   Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering  2020/10/14 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered…
   Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020  2020/11/24 10:30:00 PR Newswire
SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat…
   Aridis Pharmaceuticals Announces Third Quarter 2020 Results  2020/11/20 21:05:00 PR Newswire
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the…
   Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel  2020/10/27 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH…
   Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Lowered by Zacks Investment Research  2020/10/21 17:08:41 The Olympia Report
Aridis Pharmaceuticals (NASDAQ:ARDS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to […]
   Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering  2020/10/14 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリディス・ファ―マシュ―ティカルズ ARDS Aridis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)